# AstraZeneca shares fell 1.7% to 13,714.00 pence on Friday morning in London.

*biotech · news · 2026-05-01 · MarketScreener*

## Key points

- AstraZeneca's Truqap combo won US advisory committee backing for PTEN-deficient metastatic prostate cancer.
- Phase-three data showed Truqap reduced progression or death risk by 19% in this prostate cancer group.
- AstraZeneca's camizestrant failed to secure US advisory approval for first-line advanced breast cancer use.
- Camizestrant showed strong disease progression reduction, but data on overall survival remains immature.
- Both Truqap and camizestrant regulatory reviews are ongoing in the EU as well.

**Companies:** AstraZeneca PLC
**Countries:** United States, United Kingdom

[Read the full story on MarketScreener](https://www.marketscreener.com/news/mixed-outcome-for-astrazeneca-as-us-committee-votes-on-cancer-drugs-ce7f58d9d88df02c)

---

Canonical: https://newsio.io/n/6f799951-e8d6-4af8-b505-ffae1696f510/astrazeneca-shares-fell-1-7-to-13714-00-pence-on-friday-morning-in-london-us-foo
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works